TABLE 1.
Demographic and clinical characteristics of critically ill patients with COVID-19 who underwent BALF culture and BALF GM testinga
| Variable | No. of patientsb | % |
|---|---|---|
| Demographic variables | ||
| Age in yrs, median (IQR) | 65 (57–73) | |
| Female sex | 64/218 | 29 |
| Medical history | ||
| No. of coexisting conditions, median (IQR) | 1 (0–2) | |
| Obesity | 44/218 | 20 |
| Active malignant disease | 19/218 | 9 |
| Solid-organ transplantation | 9/218 | 4 |
| Cardiovascular disease | 113/218 | 52 |
| Structural lung disease | 39/218 | 18 |
| Diabetes mellitus | 49/218 | 22 |
| History of smoking | 20/218 | 9 |
| ECMO | 13/218 | 6 |
| Invasive mechanical ventilation | 156/218 | 72 |
| Noninvasive ventilation | 86/218 | 39 |
| Results of BALF mycological tests | ||
| Negative BALF GM and negative BALF culture | 158/218 | 72 |
| Positive BALF GM and negative BALF culture | 27/218 | 12 |
| Negative BALF GM and positive BALF culture | 5/218 | 2 |
| Positive BALF GM and positive BALF culture | 28/218 | 13 |
a
BALF, bronchoalveolar lavage fluid; CAPA, COVD-19-associated pulmonary aspergillosis; ECMO, extracorporeal membrane oxygenation; GM, galactomannan; IQR, interquartile range.
b
Results are presented as no. of patients/total unless otherwise indicated.